Adherence to antihypertensive medications and health outcomes among newly treated hypertensive patients

ClinicoEconomics and Outcomes Research

Volumn 3, Issue 1, 2011, Pages 47-54

  Esposti, Luca Degli ^a   Saragoni, Stefania ^a   Benemei, Silvia ^c   Batacchi, Paolo ^b   Geppetti, Pierangelo ^c   di Bari, Mauro ^c   Marchionni, Niccolò ^c   Sturani, Alessandra ^d   Buda, Stefano ^a   Esposti, Ezio Degli ^d  

^a Economics and Outcomes Research   (Italy)

^b Local Health Unit of Florence   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d POLICLINICO UMBERTO I   (Italy)

Author keywords

Acute myocardial infarction; Adherence; All cause mortality; Antihypertensive drug therapy; Stroke

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT;

ACUTE HEART INFARCTION; ADULT; AGED; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEALTH STATUS; HOSPITAL ADMISSION; HOSPITALIZATION COST; HUMAN; HYPERTENSION; ITALY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRESCRIPTION; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SENSITIVITY ANALYSIS; STROKE;

EID: 79952910927     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S15619     Document Type: Review

References (34)

1. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta analysis. JAMA. 2003; 289: 2534-2544.
2. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure lowering regimens on major cardiovascular events: second cycle of prospectively designed overviews. Lancet. 2003; 362: 1527-1535.
3. Chalmers J. Comparison of various blood pressure lowering treatments on the primary prevention of cardiovascular outcomes in recent randomised clinical trials. Clin Exp Hypertens. 2004; 26: 709-719.
4. Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. BMJ. 2008; 336: 1121-1123.
5. American Heart Association. High Blood Pressure 2009. http://www.americanheart.org/presenter.jhtml. Accessed April 24, 2009.
6. Hansson L, Lloyd A, Anderson P, et al. Excess morbidity and cost of failure to achieve targets for blood pressure control in Europe. Blood Press. 2002; 11: 35-45.
7. Gaziano TA, Bitton A, Anand S, et al. The global cost of non optimal blood pressure. J Hypertens. 2009; 27: 1472-1477.
8. Degli Esposti L, Valpiani G. Pharmacoeconomic burden of undertreating hypertension. Pharmacoeconomics. 2004; 22: 907-928.
9. Costa FV, D'Ausilio A, Bianchi C, et al. Adherence to anti-hypertensive medications: a review and update. High Blood Pressure and Cardiovascular Prevention. 2009; 16: 101-110.
10. Fitz-Simon N, Bennett K, Feely A. A review of studies of adherence with antihypertensive drugs using prescription databases. Ther Clin Risk Manag. 2005; 1: 93-106.
11. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens. 2006; 19: 1190-1196.
12. Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Safety. 2006; 15: 565-574.
13. ISPOR Medication Compliance Special Interest Group. http://www.ispor.org/sigs/medication.asp. Accessed 23 June, 2005.
14. Elliott WJ. Improving outcomes in hypertensive patients: focus on adherence and persistence with antihypertensive therapy. J Clin Hypertens. 2009; 11: 376-382.
15. Muszbek N, Brixner D, Benedict A, et al. The economic consequences of non-compliance in cardiovascular disease and related conditions: a literature review. Int J Clin Pract. 2008; 62: 338-351.
16. Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005; 43: 521-530.
17. Di Bari M, Balzi D, Roberts AT, et al. Prognostic stratification o folder persons based on simple administrative data: development and validation of the "Silver Code", to be used in emergency department triage. J Gerontol A Biol Sci Med. 2010; 65: 159-164.
18. Ministero del Lavoro, della Salute e delle Politiche Sociali. Rapporto annuale sulla attività di ricovero ospedaliero. Anno 2005. http://www.ministerosalute.it/programmazione/sdo/sezDocumenti.jsp?id=148&label=osp. Accessed April 24, 2009.
19. Breekveldt-Postma NS, Penning-van Beest FJ, Siiskonen SJ, et al. The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. Curr Med Res Opin. 2008; 24: 121-127.
20. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007; 297: 177-186.
21. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Safety. 2007; 16: 241-249.
22. Catalan VS, LeLorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value Health. 2000; 3: 417-426.
23. Kettani FZ, Dragomir A, Coté R, et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke. 2009; 40: 213-220.
24. Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009; 120: 1598-1605.
25. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006; 166: 1836-1841.
26. Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006; 166: 1842-1847.
27. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Persistent use of evidence-based pharmacotherapy in heart failure is associated with improved outcomes. Circulation. 2007; 116: 737-744.
28. Motheral BR, Fairman KA. The use of claims databases for antihypertensive drugs and associated hospitalization. Clin Ther. 1997; 19: 346-366.
29. Birnbaum HG, Cremieux PY, Greenberg PE, et al. Using health care expenditures for healthcare claims data for outcome research and pharmaco-economic analyses. Pharmacoeconomics. 1999; 16: 1-8.
30. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009; 338: b1665.
31. Elliott WJ, Plauschinat CA, Skrepnek GH, Gause D. Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies. J Am Board Fam Med. 2007; 20: 72-80.
32. Elliott WJ. Compliance strategies. Curr Opin Nephrol Hypertens. 1994; 3: 271-278.
33. Leal J, Luengo-Fernandez R, Gray A. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J. 2006; 27: 1610-1619.
34. Tarride JE, Lim M, DesMeules M, et al. A review of the cost of cardiovascular disease. Can J Cardiol. 2009; 25: e195-e202.